난소 과립막세포종 : 시장 인사이트, 역학, 시장 예측(2034년)

Ovarian Granulosa Cell Tumors - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,189,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,784,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,379,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 33,568,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

난소 과립막세포종의 주요 7 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대해 조사분석했으며, 각 지역의 시장 규모, 현재의 치료법, 미충족 요구, 신약 등의 정보를 제공하고 있습니다.

목차

제1장 주요 인사이트

제2장 난소 과립막세포종의 개요

제3장 난소 과립막세포종의 경쟁 정보 분석

제4장 난소 과립막세포종 : 시장의 개요

• 난소 과립막세포종 전체 시장 점유율 분포(2020년)
• 난소 과립막세포종 전체 시장 점유율 분포(2034년)

제5장 난소 과립막세포종 : 질환의 배경과 개요

• 서론
• 징후와 증상
• 병태생리학
• 위험 요인
• 진단

제6장 환자 여정

제7장 난소 과립막세포종 역학과 환자 인구

• 역학의 주요 조사 결과
• 전제조건과 근거 : 주요 7 시장
• 역학 시나리오 : 주요 7 시장
  • 주요 7 시장의 난소 과립막세포종 역학 시나리오(2020-2034년)
• 미국의 역학
  • 미국의 난소 과립막세포종 역학 시나리오(2020-2034년)
• 유럽 5개국의 역학 : 국가별
  • 독일의 역학
  • 프랑스의 역학
  • 이탈리아의 역학
  • 스페인의 역학
  • 영국의 역학
  • 일본의 역학

제8장 치료 알고리즘, 현재의 치료, 의료 행위

• 난소 과립막세포종 치료와 관리
• 난소 과립막세포종 치료 알고리즘

제9장 미충족 요구

제10장 난소 과립막세포종 치료의 주요 평가항목

제11장 출시 제품

제12장 신치료법

제13장 난소 과립막세포종 : 주요 7 시장 분석

• 주요 조사 결과
• 주요 7 시장의 난소 과립막세포종 시장 규모
• 주요 7 시장의 난소 과립막세포종 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7 시장 : 시장 전망

• 미국 : 시장 규모
  • 미국의 난소 과립막세포종 전체 시장 규모
  • 미국의 난소 과립막세포종 시장 규모 : 치료법별
• 유럽 5개국 : 시장 규모와 전망
• 독일 시장 규모
  • 독일의 난소 과립막세포종 전체 시장 규모
  • 독일의 난소 과립막세포종 시장 규모 : 치료법별
• 프랑스 시장 규모
• 이탈리아 시장 규모
• 스페인 시장 규모
• 영국 시장 규모
  • 영국의 난소 과립막세포종 전체 시장 규모
  • 영국의 난소 과립막세포종 시장 규모 : 치료법별
• 일본 시장 전망
  • 일본 시장 규모

제16장 난소 과립막세포종 액세스와 상환의 개요

제17장 KOL의 견해

제18장 시장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

KSA

영문 목차

영문목차

DelveInsight's "Ovarian Granulosa Cell Tumors - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Ovarian Granulosa Cell Tumors, historical and forecasted epidemiology as well as the Ovarian Granulosa Cell Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ovarian Granulosa Cell Tumors market report provides current treatment practices, emerging drugs, Ovarian Granulosa Cell Tumors market share of the individual therapies, current and forecasted Ovarian Granulosa Cell Tumors market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Ovarian Granulosa Cell Tumors treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Ovarian Granulosa Cell Tumors Disease Understanding and Treatment Algorithm

The DelveInsight Ovarian Granulosa Cell Tumors market report gives a thorough understanding of the Ovarian Granulosa Cell Tumors by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Ovarian Granulosa Cell Tumors.

Treatment

It covers the details of conventional and current medical therapies available in the Ovarian Granulosa Cell Tumors market for the treatment of the condition. It also provides Ovarian Granulosa Cell Tumors treatment algorithms and guidelines in the United States, Europe, and Japan.

Ovarian Granulosa Cell Tumors Epidemiology

The Ovarian Granulosa Cell Tumors epidemiology division provide insights about historical and current Ovarian Granulosa Cell Tumors patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Ovarian Granulosa Cell Tumors epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Ovarian Granulosa Cell Tumors Epidemiology

The epidemiology segment also provides the Ovarian Granulosa Cell Tumors epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Ovarian Granulosa Cell Tumors Drug Chapters

Drug chapter segment of the Ovarian Granulosa Cell Tumors report encloses the detailed analysis of Ovarian Granulosa Cell Tumors marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Ovarian Granulosa Cell Tumors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Ovarian Granulosa Cell Tumors treatment.

Ovarian Granulosa Cell Tumors Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Ovarian Granulosa Cell Tumors treatment.

Ovarian Granulosa Cell Tumors Market Outlook

The Ovarian Granulosa Cell Tumors market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Ovarian Granulosa Cell Tumors market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Ovarian Granulosa Cell Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Ovarian Granulosa Cell Tumors market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Ovarian Granulosa Cell Tumors market in 7MM.

The United States Market Outlook

This section provides the total Ovarian Granulosa Cell Tumors market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Ovarian Granulosa Cell Tumors market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Ovarian Granulosa Cell Tumors market size and market size by therapies in Japan is also mentioned.

Ovarian Granulosa Cell Tumors Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Ovarian Granulosa Cell Tumors market or expected to get launched in the market during the study period 2020-2034. The analysis covers Ovarian Granulosa Cell Tumors market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Ovarian Granulosa Cell Tumors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Ovarian Granulosa Cell Tumors key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Ovarian Granulosa Cell Tumors emerging therapies.

Reimbursement Scenario in Ovarian Granulosa Cell Tumors

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Ovarian Granulosa Cell Tumors domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Ovarian Granulosa Cell Tumors market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Ovarian Granulosa Cell Tumors Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Ovarian Granulosa Cell Tumors, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Ovarian Granulosa Cell Tumors epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Ovarian Granulosa Cell Tumors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Ovarian Granulosa Cell Tumors market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Ovarian Granulosa Cell Tumors market

Report Highlights:

• In the coming years, Ovarian Granulosa Cell Tumors market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian Granulosa Cell Tumors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Ovarian Granulosa Cell Tumors. Launch of emerging therapies will significantly impact the Ovarian Granulosa Cell Tumors market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ovarian Granulosa Cell Tumors
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Ovarian Granulosa Cell Tumors Report Insights

• Patient Population
• Therapeutic Approaches
• Ovarian Granulosa Cell Tumors Pipeline Analysis
• Ovarian Granulosa Cell Tumors Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Ovarian Granulosa Cell Tumors Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Ovarian Granulosa Cell Tumors Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Ovarian Granulosa Cell Tumors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Ovarian Granulosa Cell Tumors market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Ovarian Granulosa Cell Tumors total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Ovarian Granulosa Cell Tumors market size during the forecast period (2024-2034)?
• At what CAGR, the Ovarian Granulosa Cell Tumors market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Ovarian Granulosa Cell Tumors market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Ovarian Granulosa Cell Tumors market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Ovarian Granulosa Cell Tumors?
• What is the historical Ovarian Granulosa Cell Tumors patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Ovarian Granulosa Cell Tumors in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Ovarian Granulosa Cell Tumors?
• Out of all 7MM countries, which country would have the highest prevalent population of Ovarian Granulosa Cell Tumors during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Ovarian Granulosa Cell Tumors treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Ovarian Granulosa Cell Tumors in the USA, Europe, and Japan?
• What are the Ovarian Granulosa Cell Tumors marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Ovarian Granulosa Cell Tumors?
• How many therapies are developed by each company for Ovarian Granulosa Cell Tumors treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Ovarian Granulosa Cell Tumors treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Ovarian Granulosa Cell Tumors therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ovarian Granulosa Cell Tumors and their status?
• What are the key designations that have been granted for the emerging therapies for Ovarian Granulosa Cell Tumors?
• What are the global historical and forecasted market of Ovarian Granulosa Cell Tumors?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Ovarian Granulosa Cell Tumors market
• To understand the future market competition in the Ovarian Granulosa Cell Tumors market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Ovarian Granulosa Cell Tumors in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Ovarian Granulosa Cell Tumors market
• To understand the future market competition in the Ovarian Granulosa Cell Tumors market

Table of Contents

1. Key Insights

2. Executive Summary of Ovarian Granulosa Cell Tumors

3. Competitive Intelligence Analysis for Ovarian Granulosa Cell Tumors

4. Ovarian Granulosa Cell Tumors: Market Overview at a Glance

• 4.1. Ovarian Granulosa Cell Tumors Total Market Share (%) Distribution in 2020
• 4.2. Ovarian Granulosa Cell Tumors Total Market Share (%) Distribution in 2034

5. Ovarian Granulosa Cell Tumors: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Ovarian Granulosa Cell Tumors Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Ovarian Granulosa Cell Tumors Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Ovarian Granulosa Cell Tumors Treatment and Management
• 8.2. Ovarian Granulosa Cell Tumors Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Ovarian Granulosa Cell Tumors Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Ovarian Granulosa Cell Tumors: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Ovarian Granulosa Cell Tumors Market Size in 7MM
• 13.3. Ovarian Granulosa Cell Tumors Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Ovarian Granulosa Cell Tumors Total Market Size in the United States
  • 15.1.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Ovarian Granulosa Cell Tumors Total Market Size in Germany
  • 15.3.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Ovarian Granulosa Cell Tumors Total Market Size in France
  • 15.4.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Ovarian Granulosa Cell Tumors Total Market Size in Italy
  • 15.5.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Ovarian Granulosa Cell Tumors Total Market Size in Spain
  • 15.6.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Ovarian Granulosa Cell Tumors Total Market Size in the United Kingdom
  • 15.7.2. Ovarian Granulosa Cell Tumors Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Ovarian Granulosa Cell Tumors Total Market Size in Japan
  • 15.8.3. Ovarian Granulosa Cell Tumors Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Ovarian Granulosa Cell Tumors

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료